Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds

Nat Rev Mol Cell Biol. 2016 Nov;17(11):679-690. doi: 10.1038/nrm.2016.93.

Michael S Bonkowski ¹, David A Sinclair ¹ ²

Affiliations

1 Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.
2 Department of Pharmacology, The University of New South Wales, Sydney 2052, Australia.

PMID: 27552971 DOI: 10.1038/nrm.2016.93

Abstract

The sirtuins (SIRT1-7) are a family of nicotinamide adenine dinucleotide (NAD⁺)-dependent deacylases with remarkable abilities to prevent diseases and even reverse aspects of ageing. Mice engineered to express additional copies of SIRT1 or SIRT6, or treated with sirtuin-activating compounds (STACs) such as resveratrol and SRT2104 or with NAD⁺ precursors, have improved organ function, physical endurance, disease resistance and longevity. Trials in non-human primates and in humans have indicated that STACs may be safe and effective in treating inflammatory and metabolic disorders, among Others. These advances have demonstrated that it is possible to rationally design molecules that can alleviate multiple diseases and possibly extend lifespan in humans.

Name
Email *

	Sorry, but the email address you supplied was invalid.